Compare Pfizer Inc (PFE) vs Trade Desk Inc (TTD) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

The Trade Desk (TTD) trades at $18.25, down 1.83% with bearish technical signals. Revenue grew to $2.9B in 2025 with strong 77.8% gross margins, though Q1 2026 EPS missed expectations. Recent executive appointments and the Publicis dispute settlement provide operational stability. The stock faces headwinds from slowing growth and competitive pressure from tech giants.

TTD presents a value opportunity at 21x P/E with 49% analyst buy ratings and $25.23 price target upside. Risks include persistent revenue deceleration and market share loss to walled gardens. The company's profitability and strategic partnerships support long-term potential despite near-term challenges.